Startup
Developing innovative therapies for chronic inflammatory conditions in cardiovascular disease
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round ProKardia raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
| University of Sydney | Accelerator | - |
Companies ProKardia acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming ProKardia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The University of Sydney has launched a $25 million pre-seed fund to back ventures spun out of its research, naming five initial investments across carbon capture, diabetes treatment, inhaled medicines and cardiovascular devices.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.